The Cytel Blog: Perspectives on Enquiry & Evidence

Clinical researchers, seeking to understand the statistical benefits of a common Phase 2 oncology design, now have a..

A combination of industry and policy forces have recently changed the shape of Australia’s R&D sector, making it a..

Randomized control trials (RCTs) are the gold standard for estimating the efficacy of a treatment. They allow us to..

Real world evidence (RWE) provides a large and growing source of insights into drug uptake and safety. It is..

The issue of delayed treatment effects in immuno-oncology was demonstrated during a FDA-Industry sponsored workshop..

The FDA “Real-Time Oncology Review (RTOR)”[1] is an “FDA project started in 2018 to facilitate earlier submission of..

Currently, there are many treatment options for Cancer such as, Immunotherapy, Radiation Therapy, Chemotherapy etc. If..

Synthetic control arms (SCAs) are best suited for situations when a single arm trial is run in a patient population..

Scientists at Cytel recently published a paper in the Journal of the American Medical Association (JAMA). Among the..